Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines Review uri icon

Overview

MeSH Major

  • Myelodysplastic Syndromes

abstract

  • The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

publication date

  • January 2015

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4696005

PubMed ID

  • 25736003

Additional Document Info

start page

  • 261

end page

  • 72

volume

  • 13

number

  • 3